THIS PAGE IS TEMPORARILY UNDER CONSTRUCTION WHILE ENHANCEMENTS ARE UNDERWAY. Drug shortage data continues to be updated while under construction.
Current and Resolved Drug Shortages and Discontinuations Reported to FDA
Report a Drug Shortage |
Contact Us |
FAQ |
Background Info |
Get Email Alerts |
Download Current Drug Shortages
Start Over | Back to Previous Screen
Cisplatin Injection
Status: Currently in Shortage
»Date first posted:
02/10/2023
»Therapeutic Categories: Oncology; Pediatric
Accord Healthcare Inc. (Revised 07/13/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Cisplatin, Injection, 1 mg/1 mL (NDC 16729-288-11) | Not available | Marketed by Accord Healthcare. Accord does not have product available at this time. Will update upon future releases. | |
| Cisplatin, Injection, 1 mg/1 mL (NDC 16729-288-38) | Not available | Marketed by Accord Healthcare. Accord does not have product available at this time. Will update upon future releases. | |
| Cisplatin, Injection, 1 mg/1 mL (NDC 68001-283-27) | Not available | Marketed by BluePoint Laboratories. Accord does not have product available at this time. Will update upon future releases. | |
| Cisplatin, Injection, 1 mg/1 mL (NDC 68001-283-32) | Not available | Marketed by BluePoint Laboratories. Accord does not have product available at this time. Will update upon future releases. |
Fresenius Kabi USA, LLC (Revised 09/18/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Cisplatin, Injection, 1 mg/1 mL (NDC 63323-103-51) | Backordered. Next release September 2023. | Demand increase for the drug | |
| Cisplatin, Injection, 1 mg/1 mL (NDC 63323-103-65) | Backordered. Next release September 2023. | Check wholesalers for inventory | Demand increase for the drug |
| Cisplatin, Injection, 1 mg/1 mL (NDC 63323-103-64) | Backordered. Next release September 2023. | Demand increase for the drug |
Gland Pharma Limited (Revised 09/18/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Cisplatin, Injection, 1 mg/1 mL (NDC 25021-253-50) | On backorder; Estimated recovery: October 2023 | Marketed by Sagent. New launch. | Demand increase for the drug |
| Cisplatin, Injection, 1 mg/1 mL (NDC 25021-253-51) | Available. On allocation due to high demand | Marketed by Sagent. New launch. | Demand increase for the drug |
Hikma Pharmaceuticals USA, Inc. (Revised 07/28/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Cisplatin, Injection, 1 mg/1 mL (NDC 0143-9504-01) | Temporarily on backorder. | Additional lots will be available in the August 2023 timeframe. Product will be made available as it is released. | |
| Cisplatin, Injection, 1 mg/1 mL (NDC 0143-9505-01) | Temporarily on backorder. | Additional lots will be available in the September 2023 timeframe. Product will be made available as it is released. |
HQ Specialty Pharma (Revised 09/18/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Cisplatin, Injection, 1 mg/1 mL (NDC 44567-511-01) | Available on allocation | Marketed by WG Critical Care | Demand increase for the drug |
| Cisplatin, Injection, 1 mg/1 mL (NDC 44567-530-01) | Available on allocation | Marketed by WG Critical Care | Demand increase for the drug |
Qilu Pharmaceutical Co., Ltd. (Revised 09/18/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Cisplatin, Injection, 50 mg/50 mL (NDC 60505-6277-0) | Not available. All imported product has been distributed. | Qilu Pharmaceutical Co., Ltd., in coordination with the U.S. FDA and Apotex Corp., has initiated temporary importation of CISplatin Injection 50 mg/50 mL (1 mg/mL) vials into the U.S. market to address a drug shortage of CISplatin. Product is available via Apotex Corp.’s authorized distributors. Contact your primary wholesaler/distributor to place orders. | Demand increase for the drug |
Teva Pharmaceuticals (Revised 09/18/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Cisplatin, Injection, 50 mg/50 mL (NDC 0703-5747-11) | Allocating available supply | Demand increase for the drug | |
| Cisplatin, Injection, 100 mg/100 mL (NDC 0703-5748-11) | Allocating limited supply | Demand increase for the drug |